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ABSTRACT 
The nuclear pore complex (NPC) is one of the largest and most complex protein assemblies 
in eukaryotic cells, and it facilitates and regulates the bidirectional transfer of molecules 
between the nucleus and cytoplasm. One of the essential functions of the NPC is to directly 
regulate the export of mature mRNAs, but the mechanism is not well understood, especially 
in humans. Export of mRNA is completed at the cytoplasmic side of the NPC, where ATPase 
activity of the DEAD-box helicase DDX19 is specifically activated by the NPC components 
Gle1, Nup42, and Nup214. The mRNA export factor Gle1 is an essential nucleoporin, and 
Gle1 dysfunction has been linked to human diseases. We show that the Gle1•Nup42 
interaction is highly conserved with X-ray crystal structures and that the thermostability of 
Gle1 is highly dependent on Nup42. We also find that disease-linked mutants of Gle1 show 
strongly altered thermostability. Analysis of DDX19 steady-state ATPase activity reveals a 
novel mode of activation by Gle1 in humans. Structural studies of DDX19 complement the 
biochemical characterization of DDX19, and we have proposed a working model for the 
DDX19 catalytic cycle. An outstanding question remains in this model, as the details of 
DDX19-mediated removal of the export factor NXF1•NXT1 from mRNA are unknown. We 
describe a method for large-scale purification of retroviral constitutive transport element 
(CTE) RNA, which hijacks NXF1•NXT1 to be exported through the NPC, for X-ray 
crystallographic studies of a NXF1•NXT1•CTE complex. Together, these results provide a 
detailed structural and functional description of mRNA export regulation by the NPC and a 
framework for understanding the molecular basis of human disease linked to Gle1 and viral 
proliferation.   
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INTRODUCTION 
A hallmark of the evolution separating eukaryotes from bacteria is the subdivision of cells 
into specialized, membrane-bound compartments. One such membrane bilayer is found in 
the nuclear envelope, separating genetic information contained in the nucleus from the 
greater cell cytoplasm. The nuclear pore complex (NPC) is nature’s largest protein channel, 
and it is the sole gateway for the bidirectional transport of macromolecules between the 
nucleus and cytoplasm of eukaryotic cells. Although the NPC is massive, with a diameter of 
~1000 Å and a total mass of ~120 MDa, the eightfold-symmetric complex is only composed 
of approximately 30 unique nuclear pore proteins (nucleoporins) which arrange into a 
symmetric, doughnut-shaped core and asymmetric nuclear basket and cytoplasmic filament 
subcomplexes (Hoelz et al., 2011) (Figure 1). Whereas the composite structure of the 
symmetric core of the NPC has recently been elucidated, the architecture of the asymmetric 
nuclear and cytoplasmic faces is yet to be determined (Kosinski et al., 2016; Lin et al., 2016). 
Here, we focus on studying the structure and function of the mRNA export machinery of the 
NPC, located at the cytoplasmic face (circled in Figure 1). 
The central dogma of molecular biology poses that genetic information flows from 
DNA to protein in a two-step process. First, DNA is converted to RNA through the process 
of transcription, and then protein is synthesized from RNA in the process of translation. The 
precisely controlled handoff between transcription and translation is a fundamental 
biological process that is necessary for all cellular function. In eukaryotes, transcription and 
translation are spatially and temporally segregated in the nucleus and cytoplasm, 
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respectively. Whereas prokaryotes couple the two processes, the separation allows 
eukaryotes to have far greater control and regulation of gene expression, contributing to the 
domain’s greater diversity of form and function (Hoelz et al., 2011). 
Messenger RNA (mRNA), the template for protein synthesis, is transcribed from 
DNA in the nucleus. After post-transcriptional processing, such as splicing and addition of a 
5’ cap and poly(A)+ tail, the mature mRNA is packaged with additional proteins into an 
export-competent messenger ribonucleoprotein (mRNP) complex (Stewart, 2010). This 
mRNP interacts with and shuttles through the NPC diffusion barrier formed by phenylalanine 
glycine (FG) repeats in the central channel of the pore (Katahira et al., 1999). At the 
cytoplasmic face of the NPC, the mRNP encounters machinery that releases the mRNA into 
the cytoplasm for translation, but the molecular mechanism of this mRNP remodeling event 
remains to be elucidated (Lund and Guthrie, 2005).  
This work describes efforts to characterize the cytoplasmic-side mRNA export 
machinery of the NPC using an interdisciplinary approach, combining structural studies and 
biochemical analyses. The first chapter explores the interaction between the mRNA export 
factor Gle1 and the cytoplasmic filament nucleoporin Nup42, which was previously 
uncharacterized. The molecular details of the Gle1•Nup42 interaction are set into the greater 
context of mRNA export regulation by the NPC in the second chapter. Stimulation of the 
mRNA export factor DDX19, the catalytic center of the export machinery, is reconstituted 
in vitro, providing new insights into the role of nucleoporins in the termination of mRNA 
export. Finally, the third chapter describes the crystallography-scale synthesis and 
purification of the viral constitutive transport element (CTE) RNA, which provides a 
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framework for the structural study of the specific interaction between the RNA-binding 
heterodimeric export factor NXF1•NXT1 and CTE-RNA that can advance knowledge of the 
precise mechanism for mRNP remodeling by DDX19. Together, these results provide a 
detailed structural and functional description of mRNA export regulation by the NPC and a 
framework for understanding the molecular basis of human disease linked to Gle1 and viral 
proliferation. 
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Figure 1. The mRNA export machinery of the nuclear pore complex. (a) Cartoon 
schematic of the human nuclear pore complex (NPC). The circle highlights the region of the 
NPC to which the proteins used in this study localize. (b) Domain schematics for 
nucleoporins used in this study. Protein names and boundaries correspond to the human 
proteins (Adapted with permission from Lin et al., 2018). 
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C h a p t e r  1  
STRUCTURAL AND FUNCTIONAL CHARACTERIZATION OF 
THE GLE1•NUP42 INTERACTION 
 
This chapter contains results generated by colleagues to confer a coherent story and flow of 
logic. Experiments conducted by others will be explicitly declared in blue. This chapter was 
adapted from: 
 
Daniel H. Lin, Ana R. Correia*, Sarah W. Cai*, Ferdinand M. Huber, Claudia A. Jette, 
André Hoelz (2018). Structural and functional analysis of mRNA export regulation by the 
nuclear pore complex, Nature Communications, accepted April 27, 2018. 
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Introduction 
Gle1 is an essential mRNA export factor that is required for poly(A)+ mRNA export, 
in addition to its other functional roles in the cell. The majority of Gle1 studies have been 
conducted in budding yeast, S. cerevisiae (sc), where Gle1 interacts with multiple binding 
partners. One of these partners is Dbp5 (DDX19 in humans), which is a conserved essential 
DEAD-box family helicase (Kendirgi et al., 2003; Montpetit et al., 2011; Rollenhagen et al., 
2004). The association of the Gle1 C-terminal domain (Gle1CTD) and the Dbp5 C-terminal 
domain (Dbp5CTD) is mediated by the small molecule inositol hexaphosphate (IP6), and the 
structure of this complex has been solved (Montpetit et al., 2011). Gle1 is also known to 
interact with Nup42, a cytoplasmic filament nucleoporin, via their C-terminal regions, but 
otherwise, the role of the interaction between Gle1 and Nup42 is not well understood 
(Kendirgi et al., 2005). Previous studies in S. cerevisiae have shown that Gle1 is able to 
localize to the nuclear envelope in a nup42∆ knockout strain at 23°C. However, after heat 
shock to 42°C, Gle1 mislocalizes and the cells experience defects in mRNA export, 
suggesting that Nup42 strengthens the interaction between Gle1 and the NPC but is only 
necessary during heat shock (Rollenhagen et al., 2004). In humans (hs), Gle1 exists in two 
isoforms, as a result of two differing splice variants. Gle1A lacks 43 residues at the C-
terminus that are required for Nup42 binding, and in the cell, this isoform remains 
cytoplasmic. The more abundant Gle1B, homologous to scGle1, is capable of binding Nup42 
and localizes to the NPC (Kendirgi et al., 2005). Throughout this text, Gle1 will refer to the 
Gle1B isoform of hsGle1.  
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In humans, the Gle1•Nup42 interaction is particularly interesting in the context of 
human health and disease. A recent study has linked three specific mutations in Gle1 to 
amyotrophic lateral sclerosis (ALS), and other mutations identified in Gle1 have been linked 
to lethal congenital contracture syndrome (LCCS1) and lethal arthrogryposis with anterior 
horn cell disease (LAAHD) (Kaneb et al., 2015; Nousiainen et al., 2008). LCCS1 and 
LAAHD are autosomal recessive motor neuron disorders which result in fetal death before 
the 32nd gestational week, and LCCS1 is the more phenotypically severe of the two. In both 
diseases, patients have a characteristic three amino acid (PFQ) insertion at residue 144 in the 
coiled-coil region of Gle1, termed FinMajor. LCCS1 patients are homozygous for the FinMajor 
mutation, while LAAHD patients are compound heterozygous for the FinMajor mutation and 
a single amino acid substitution in Gle1CTD (V617M and I684T). In a FinMajor heterozygous 
patient diagnosed with LCCS1 based on phenotypic similarities, a third mutation (R569H) 
was identified, suggesting that the R569H has a stronger effect compared to the V617M and 
I684T substitutions (Nousiainen et al., 2008). ALS is a fatal neurodegenerative disease that 
has been recently characterized as an RNA metabolism disorder. The three mutations 
identified in Gle1 consist of a nonsense mutation that truncates the protein at residue 70, a 
splice-site mutation that replaces the C-terminal 44 residues of Gle1 with a novel 88-residue 
stretch, and a missense mutation that results in the substitution R697C. The latter two 
mutations both affect the Nup42 binding domain of Gle1, which is the interaction of interest 
presented here (Kaneb et al., 2015). Understanding the effects of these mutations on Gle1 in 
the context of the NPC and mRNA export will help increase our understanding of the 
molecular-level causes of motor neuron diseases.  
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In this chapter, we present a structural and functional analysis of the role of Nup42 
as a binding partner for Gle1, and we examine the effect of disease mutations on Gle1 
function. 
 
Crystallization of yeast and human Gle1•Nup42 
To study the molecular details of the Gle1•Nup42 interaction, we reconstituted the complex 
in vitro with purified, recombinant proteins and pursued an X-ray crystal structure to study 
the interaction at atomic resolution. First, we sought to determine the minimal span of Nup42 
required to interact with Gle1CTD, which refers to the previously solved domain containing 
residues 244-538 (Montpetit et al., 2011) and the analogous residues (382-698) in the human 
protein (domain boundaries are schematized in introduction Figure 1 and Figure S1). The 
rationale for this experiment lies in the hypothesis that residues of Nup42 at the Gle1CTD-
interaction interface will be structured, eliminating any disordered regions that would 
interfere with crystallization attempts. Using constructs of Nup42 fused to a glutathione S-
transferase (GST) affinity tag and Gle1CTD fused to SUMO, we overexpressed yeast and 
human GST-Nup42 and SUMO-Gle1CTD in E. coli, pulling down SUMO-Gle1CTD from the 
bacterial lysate (Figure S1). The minimal Gle1CTD-binding region on Nup42 was mapped to 
residues 397-430 in yeast and the analogous residues 379-423 in humans, termed the Gle1-
binding motif (GBM) (Introduction Figure 1). Preliminary in vivo localization experiments 
in S. cerevisiae confirmed that Nup42GBM-mCherry was sufficient for rescue of heat shock 
induced mislocalization of Gle1-GFP (Figure S2). The minimal Nup42GBM constructs were 
coexpressed and purified with Gle1CTD. Crystals of scGle1CTD•Nup42GBM were obtained in 
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the tetragonal space group P43212. The structure was solved using molecular replacement 
and refined to 1.75 Å resolution with an Rwork/Rfree of 18.5/21.1.Crystals of 
hsGle1CTD•Nup42GBM were obtained in the monoclinic space group C2. The structure was 
solved using molecular replacement and refined to 2.8 Å resolution with an Rwork/Rfree of 
24.5/27.4. Details of data collection and refinement statistics are given in Table 1. 
 
Nup42 interacts with Gle1 via a conserved binding motif 
The structures of human and yeast Gle1CTD•Nup42GBM show remarkable similarity, 
especially when considered in the context of a third structure of the thermophilic fungus C. 
thermophilum (ct) Gle1CTD•Nup42GBM. In all three species, Nup42GBM folds into a compact 
helical secondary structure that buries a solvent-exposed hydrophobic surface on GleCTD, 
which also adopts the same fold in all three species (Figure 1). In yeast, scNup42GBM residues 
F409, F414, P420, and P423 appear to be critical for folding of the Nup42GBM hydrophobic 
core around scGle1CTD residues W451 and Y488. These key residues are conserved across 
the three species (hsNup42GBM residues F401/F406/P412/P415 recognize hsGle1CTD 
residues W602/Y637; ctNup42GBM residues F533/F539/P544/P547 recognize ctGle1CTD 
residues W447/Y484) (Figure 1e). The structural similarities are consistent with a multi-
species sequence alignment of Gle1CTD, in which the residues involved in Nup42-binding are 
highly conserved (Figure S3). The persistence of this interaction through evolution supports 
an important functional role for the complex. To validate the structure, we generated variants 
of scNup42GBM containing mutations in key residues from the interface: alanine substitutions 
F409A, F414A, L416A, P423A and charge-introducing substitutions L416R, F409D, 
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F414D, and a F409D/F414D double mutant. While single alanine substitutions in the 
hydrophobic core did not abolish binding to scGle1CTD, consistent with the extensive 
interaction surface, the highly charged aspartate substitutions (F414D and F409D/F414D) 
were able to disrupt the interaction on a SEC column (Figure 2). 
 
Gle1 thermostability is dependent on Nup42 
During the expression and purification of Gle1CTD•Nup42GBM, we observed that apo Gle1CTD 
had far lower expression yields than the complex and was unstable and prone to aggregation. 
In yeast, addition of IP6 to the purification buffers reduced precipitation, but the yield was 
still far lower than that obtained with coexpressed scGle1CTD•Nup42GBM. With the human 
proteins, apo hsGle1CTD expression yields were even more abysmal, and IP6 addition did not 
improve stability during purification. Taking into context the temperature-sensitive role of 
Nup42 in Gle1 localization to the NPC and the hydrophobic nature of the interaction 
interface, we tested the effects of Nup42GBM and IP6 on Gle1 thermostability. Using two 
complementary methods, differential scanning fluorimetry (DSF) and a protein solubility 
assay, we measured the effects of Nup42GBM and IP6 on the melting temperature (Tm) of 
Gle1CTD. In yeast, we observed a dramatic effect for each of IP6 and scNup42GBM, with shifts 
in Tm from 22°C for apo scGle1CTD to 37°C and 46°C, respectively. The combined effect 
was even greater, shifting the Tm to 53°C. In humans, a similar effect was observed for 
hsNup42GBM, which shifted the Tm from 37°C for apo hsGle1CTD to 50°C. When copurified 
with hsNup42GBM, expression yields increased 100-fold for the complex over apo hsGle1CTD. 
IP6 did not have a significant effect on human Gle1CTD thermostability. Remarkably, 
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apo Gle1CTD is unstable below the physiological growth temperatures of 30°C in yeast and 
37°C in humans (Figure 3). These results suggest an important role for cofactors in Gle1 
thermostability and suggest that the main role of Nup42GBM is to ensure proper folding of 
Gle1, consistent with the heat shock-dependent mislocalization of Gle1 in vivo. 
 
Gle1 disease mutants have altered thermostability 
We next generated the hsGle1CTD point mutants implicated in disease (LCCS1 mutation 
R569H, LAAHD mutations V617M and I684T, and ALS mutation R697C) to investigate 
the functional effect of the mutations on hsGle1CTD•Nup42GBM thermostability. Strikingly, 
all three LAAHD/LCCS1 mutants displayed a lower Tm relative to 
WT hsGle1CTD•Nup42GBM, with the R569H mutant showing the greatest defect in 
thermostability with a shift from 50°C to 40°C, correlating well with its more severe 
phenotype. Although the ALS point mutation did not appear to have an effect on 
thermostability, the LAAHD/LCCS1 mutant analysis suggests a possible role for Gle1-
misfolding in disease (Figure 4). 
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Figure 1. A conserved mechanism for Gle1•Nup42 complex formation. Experimental 
data presented in panels c and g of this figure have been conducted by A.R.C. (a-c) Crystal 
structures of (a) S. cerevisiae, (b) H. sapiens, or (c) C. thermophilum Gle1CTD•Nup42GBM. 
(d) Superposition of the structures of S. cerevisiae, H. sapiens, and C. thermophilum 
Gle1CTD•Nup42GBM, with same coloring as in (a-c). (e-g) Zoom views of (e) S. cerevisiae, (f) 
H. sapiens, or (g) C. thermophilum Gle1CTD•Nup42GBM interactions with residues mediating 
the interaction labeled. 
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Figure 2. Mutational analysis of S. cerevisiae 
Gle1CTD•Nup42GBM. This experiment was 
conducted together with D.H.L.; S.W.C. 
generated the mutants for analysis. (a, b) SEC 
analysis of the effect of mutations in Nup42GBM on 
Gle1CTD binding. Purified Gle1CTD was mixed 
with the indicated Nup42GBM mutants and 
loaded on a Superdex 75 10/300 GL column. SEC 
profiles of Gle1CTD (black), Nup42GBM (grey), and 
Gle1CTD preincubated with Nup42GBM (blue) are 
shown as controls. SEC profiles of Nup42GBM 
mutants preincubated with Gle1CTD are colored 
green for wild-type levels of complex formation, 
orange for reduced binding, or red for complete 
disruption. The gray bar indicates the fractions 
visualized with Coomassie-stained SDS-PAGE 
gels. 
  14 
 
  15 
Figure 3. Gle1 thermostability analysis. (a, b) Differential scanning fluorimetry analysis 
of (a) S. cerevisiae or (b) H. sapiens Gle1CTD thermostability in the presence and absence of 
Nup42GBM and IP6. Exposure of hydrophobic residues was monitored by an increase in 
relative fluorescence units (RFUs). Curves represent the average of three experiments. (c-d) 
(c) S. cerevisiae or (d) H. sapiens Gle1CTD and Gle1CTD•Nup42GBM were incubated at the 
indicated temperatures in the absence or presence of IP6 for 30 minutes prior to 
centrifugation. Pelleted (P) and soluble (S) fractions were analyzed by SDS-PAGE and 
visualized by Coomassie staining. Red arrows indicate the temperature at which more than 
50% of total Gle1CTD pelleted. 
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Figure 4. Thermostability of human disease variants of Gle1CTD. Exposure of 
hydrophobic residues was monitored by an increase in relative fluorescence units (RFUs). 
Curves represent the average of three experiments. 
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Table 1. 
Data collection and refinement statistics for S. cerevisiae and H. sapiens 
Gle1CTD•Nup42GBMstructures 
 
 scGle1CTD•Nup42GBM hsGle1CTD•Nup42GBM  
Data collection   
Space group P43212 C2 
Cell dimensions     
    a, b, c (Å) 64.5, 64.5, 361.7 163.7, 69.2, 93.0 
    α, β, γ (°) 90.0 90.0 90.0 90.0, 90.6, 90.0 
Resolution (Å) a,b 50.0–1.75 (1.81–1.75) 50.0–2.8 (2.9–2.8) 
Rmeas b 12.4 (127.0) 10.7 (144.3) 
I / σI b 16.4 (1.3) 10.1 (1.1) 
Completeness (%) b 99.3 (93.5) 99.2 (97.8) 
Redundancy b 21.8 (10.5) 3.8 (3.5) 
   
Refinement   
Resolution (Å) 47.3–1.75 46.8–2.8 
No. reflections 85,335 20,826c 
Rwork / Rfree 18.5/21.1 24.5/27.4 
No. atoms 7,314 5,835 
    Protein 6,674 5,794 
    Ligand/ion 8 12 
    Water 632 29 
B-factors 39 59 
    Protein 39 59 
    Ligand/ion 43 63 
    Water 43 31 
R.m.s. deviations   
    Bond lengths (Å) 0.007 0.003 
    Bond angles (°) 1.1 0.6 
aDiffraction data were obtained from a single crystal 
bValues in parentheses are for highest-resolution shell. 
cRefinement was performed with ellipsoidally truncated data 
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C h a p t e r  2  
BIOCHEMISTRY OF DDX19 ACTIVATION BY THE NPC 
 
This chapter contains results generated by colleagues to confer a coherent story and flow of 
logic. Experiments conducted by others will be explicitly declared in blue. This chapter was 
adapted from: 
 
Daniel H. Lin, Ana R. Correia*, Sarah W. Cai*, Ferdinand M. Huber, Claudia A. Jette, 
André Hoelz (2018). Structural and functional analysis of mRNA export regulation by the 
nuclear pore complex, Nature Communications, accepted April 27, 2018. 
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Introduction 
The DEAD-box family helicase DDX19 (Dbp5 in fungi) is an ATPase that binds mRNA and 
is responsible for the terminal catalytic step in mRNA export by the NPC. DEAD-box 
proteins are characterized by their RNA-dependent ATPase activity and the presence of two 
RecA-like domains (DDX19NTD and DDX19CTD) (Weirich et al., 2006; Dossani et al., 2009; 
Montpetit et al., 2011). DDX19/Dbp5 exhibits very weak ATPase activity alone, and it 
requires RNA and stimulation by nucleoporins for function (Alcázar-Román et al., 2006; 
Montpetit et al., 2011; Weirich et al., 2006). The major binding partner and activator for 
DDX19/Dbp5 is Gle1, and the two proteins interact via their C-terminal domains (Alcázar-
Román et al., 2006; Montpetit et al., 2011; Weirich et al., 2006; Noble et al., 2011). From 
our structures of Gle1CTD•Nup42GBM, we know that the Nup42GBM interaction surface is 
spatially distinct from the surface on Gle1CTD recognized by DDX19/Dbp5. In yeast, IP6 is 
required to form a complex between Gle1CTD and Dbp5CTD, and it is also required for Gle1-
mediated stimulation of Dbp5 ATPase activity (Alcázar-Román et al., 2006; Montpetit et al., 
2011; Weirich et al., 2006; Noble et al., 2011).  
Although reconstitution of fully activated human DDX19 has not yet been achieved, 
in vitro studies of the yeast proteins have revealed a combined stimulatory effect of Gle1, 
IP6, and RNA on the steady-state ATPase activity of Dbp5. The precise mechanism by which 
these factors activate the enzyme is unclear, especially in humans (Noble et al., 2011; 
Montpetit et al., 2011). Furthermore, the roles of the cytoplasmic filament nucleoporins 
Nup42 and Nup214 (Nup159 in yeast) in the DDX19 catalytic cycle are not well understood. 
As discussed in the previous chapter, Nup42 functions in stabilizing the Gle1CTD fold, but 
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whether it directly affects DDX19 activity is unknown. The N-terminal domain of Nup214 
is required for localization of DDX19 to the NPC, but its role in DDX19 catalytic activity is 
not well understood (Schmitt et al., 1999; von Moeller et al., 2009; Napetschnig et al., 2009). 
Nup214/Nup159 have been shown to inhibit RNA-mediated stimulation of DDX19/Dbp5, 
but the addition of Gle1 in both species rescues this inhibition, so the precise functional role 
of Nup214 also remains to be determined (von Moeller et al., 2009; Napetschnig et al., 2009). 
Here, we report reconstitution of a fully stimulated DDX19 system in vitro, revealing 
an IP6-independent mechanism that appears to be conserved in metazoans. Taking the 
biochemical data presented here together with concurrent X-ray crystallographic studies, we 
discovered the precise mechanism by which Gle1 activates DDX19 in humans and a novel 
stimulatory role for Nup214 in the context of Gle1-mediated DDX19 activation. 
 
Reconstitution of DDX19 activity in vitro 
To assay the stimulatory effect of NPC components on DDX19 activation in humans, we 
modified a previously described colorimetric NADH-coupled ATPase assay designed for 
Dbp5 (Montpetit et al., 2012). Human DDX19 exhibited much weaker activity than Dbp5, 
so the human protein concentrations were increased by 5-fold to generate enough signal to 
fit the NADH colorimetric decay. Compared to the yeast proteins, we observed a similar role 
for RNA and Gle1CTD on DDX19 stimulation, where each stimulates the enzyme individually 
and together exert a greater combined effect (Figures 1 and S4). The addition of Nup42GBM 
only conferred a modest additional stimulatory effect compared to apo Gle1CTD in both yeast 
and humans, which appeared to be related to the thermostability of Gle1CTD, as the assays 
were conducted at temperatures greater than the Tm of apo Gle1CTD. The effect of Nup42GBM 
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was more pronounced when the assay was conducted at 37°C for both yeast and human 
proteins, further suggesting that Nup42CTD does not directly stimulate DDX19 (Figures 1 and 
S4). Rather, it acts allosterically through stabilization of the Gle1 fold.  
 
Gle1-mediated DDX19 activation is independent of IP6 in humans 
In yeast, IP6 is required to both form the Gle1•Dbp5 complex and to observe Gle1-dependent 
stimulation of Dbp5 (Alcázar-Román et al., 2006; Montpetit et al., 2011; Weirich et al., 2006; 
Folkmann et al., 2011). Strikingly, we found that while RNA and Gle1 activated DDX19 
similarly in both humans and yeast, IP6 did not appear to be necessary for Gle1-mediated 
stimulation of DDX19 in the human system. IP6 is not required for complex formation 
between hsGle1 and DDX19 (Figure S5), and Gle1CTD stimulated DDX19 to the same level 
with and without IP6 present (Figure 1). Furthermore, the IP6 effect in yeast is concentration 
dependent, saturating around 1 µM (2-fold excess over Dbp5), whereas in humans, there is 
no observable stimulation of DDX19 up to 100 µM IP6, the upper bound for total cellular IP6 
concentration (Figure 2a-b) (Shears, 2001). 
Further insights into the molecular basis of this differential dependence on IP6 come 
from examining more closely the structures of Gle1CTD. IP6 has six phosphate groups, 
harboring a strong total negative charge. Studying the surface electrostatic potential of the 
Dbp5/IP6 interaction interface on Gle1CTD, we find that in both S. cerevisiae and C. 
thermophilum, there exists a highly charged basic pocket that readily accommodates the IP6 
molecule. However, the analogous surface on hsGle1CTD does not harbor the same 
electrostatic potential (Figure 2c-g). A multispecies sequence alignment suggests that IP6 
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dependence is unique to fungi, as the conservation of charged residues implicated in IP6-
binding only extend through fungal species, not through metazoan species (Figure S5). 
Whether IP6 dependence was lost in metazoans or uniquely gained in fungi remains to be 
studied. 
 
Gle1 activates DDX19 via relief of auto-inhibition 
We then probed the mechanism of how Gle1 stimulates DDX19, supplementing structural 
and sequence data with biochemistry. X-ray crystal structures of 
hsGle1CTD•Nup42GBM•DDX19∆N53 in complex with ADP and with AMP-PMP•Mg2+, a non-
hydrolysable ATP analog, were obtained at 3.6 Å and 3.4 Å resolution, respectively. The 
construct of DDX19∆N53 used has 53 residues of the DDX19 flexible N-terminal extension 
removed to facilitate crystallization (Figure S7). From these structures, we noted a major 
difference between DDX19 and the previously solved structure of scGle1CTD•IP6•Dbp5∆N90 
(Montpetit et al., 2011). In humans, DDX19 contains an N-terminal auto-inhibitory helix that 
binds tightly between the two RecA domains (Collins et al., 2009) in the same way regardless 
of which nucleotide is present. This auto-inhibitory helix is only present in metazoan species, 
as determined by sequence conservation analysis. In the crystal structure of 
scGle1CTD•IP6•Dbp5∆N90, the lack of an auto-inhibitory helix appears to allow for a greater 
rotation of the Dbp5 N-terminal domain toward Gle1CTD such that Dbp5NTD also makes 
contact with Gle1CTD, in addition to the primary interaction interface between Gle1CTD and 
the Dbp5 C-terminal domain. In the human structure, DDX19NTD is rotated away from Gle1 
(Figure S7).  
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To describe the specific mechanism by which Gle1CTD stimulates DDX19, we 
compared the structure of apo DDX19∆N53, obtained at 2.2 Å resolution, to 
Gle1CTD•Nup42GBM-bound DDX19. We noted several conformational changes induced by 
Gle1CTD-binding: a set of loop movements and rearrangements in DDX19CTD results in lost 
interactions between DDX19CTD and the auto-inhibitory helix, ultimately causing a partial 
separation of DDX19NTD and DDX19CTD in a manner similar to the full separation seen in 
the yeast structure (Figure S8). Due to likely thermodynamic favorability of the auto-
inhibited DDX19, our structure represents an early, partially open state created by Gle1-
binding. We hypothesize the fully open state, where DDX19NTD contacts Gle1CTD similar to 
in the yeast structure, also occurs in humans and is required for DDX19 activation. In a 
previous study of the yeast proteins, a triple amino acid substitution (V513D/A516D/I520D) 
at the interface between Dbp5NTD and Gle1CTD abolished Gle1-mediated stimulation of Dbp5 
(Montpetit et al., 2011). We made the homologous triple mutation (G666D/I669D/Q673D, 
DDD mutant) in human DDX19 and observed the same detrimental effect on Gle1-mediated 
DDX19 stimulation (Figure S4g). 
Thus, the structure-based hypothesis for how Gle1CTD stimulates DDX19 activity 
poses that Gle1CTD triggers opening of the DDX19 RecA domains such that the nucleotide 
(ADP or ATP) can be exchanged and the system recycled. To test this hypothesis, we made 
several variants of DDX19 for biochemical analysis: DDX19∆N53 is the crystallized 
construct: DDX19S60D/K64D is mutated in two residues that are critical for interaction between 
the auto-inhibitory helix and DDX19NTD, DDX19∆N67 has the auto-inhibitory helix fully 
truncated, and DDX19∆N91 further removes mobile residues, including the auto-inhibitory 
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helix (Figure 3a). These mutants all exhibited higher basal ATPase activity than DDX19WT, 
suggesting that removal of the auto-inhibitory helix is a rate limiting step in the reaction. 
Furthermore, the fully stimulated levels of the hyperactive mutants approached yeast Dbp5 
activity levels, suggesting the presence of the auto-inhibitory helix was a reason for the low 
activity observed with the human proteins. Addition of RNA suppressed the hyperactive 
mutants back down to WT levels, so the RNA-DDX19 interaction may be a new rate-limiting 
step when the auto-inhibitory helix is not present. Finally, we observed very modest 
additional stimulation by Gle1CTD•Nup42GBM and RNA combined over RNA-mediated 
stimulation alone in the helix mutants, which indicates that Gle1CTD•Nup42GBM does not 
have a major role outside relief of auto-inhibition. On the other hand, in DDX19WT, the 
combined effect of Gle1CTD•Nup42GBM and RNA is significantly higher than either alone 
(Figure 3b). Thus, we conclude that Gle1 activates DDX19 by allowing formation of an open 
state where the auto-inhibitory helix is displaced. 
 
Nup214 stimulates DDX19 in the presence of Gle1 
Nup214 is a cytoplasmic filament protein that binds DDX19 via the same interface as RNA, 
so it inhibits RNA-mediated stimulation of DDX19, as described previously. In addition, it 
has been shown that Gle1 can rescue this inhibition in yeast and return the enzyme to fully 
stimulated levels as achieved by Dbp5WT (von Moeller et al., 2009; Napetschnig et al., 2009; 
Noble et al., 2011). We observed a similar effect with the human proteins, but we also 
observed additional stimulation by Nup214 in the combined presence of 
Gle1CTD•Nup42GBM, RNA, and Nup214 (Figure 3b). We found a modest concentration 
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dependent stimulatory effect by Nup214 in the presence of Gle1, which was amplified in 
limiting amounts of Gle1CTD•Nup42GBM. Furthermore, we observed that Nup214 inhibited 
the hyperactive DDX19 mutants to levels of activity similar to DDX19WT (Figure 3c). This 
apparent contradiction of Nup214 being both stimulatory and inhibitory may be reconciled 
in a model where Nup214 aids Gle1 in separating the RecA domains of DDX19, as 
crystallographic data shows the interface for Nup214 binding is between the RecA domains 
of DDX19 (Napetschnig et al., 2009). In this case, Nup214 accelerates formation of the open 
state, but it must be removed for RNA to bind the enzyme and form the catalytically 
competent closed state. Further studies are required to determine the rate-limiting steps and 
precise order of events in the DDX19 catalytic cycle. 
 
Gle1 disease mutants are not deficient in DDX19 activation 
We mapped the LAAHD/LCCS1/ALS point mutations to the crystal structure of 
hsGle1CTD•Nup42GBM•DDX19∆N53, but the mutations did not appear to affect Gle1CTD 
binding to either Nup42GBM or DDX19. In comparing the ability of the mutants to stimulate 
DDX19 ATPase activity relative to wild-type, there was no significant difference between 
the mutant Gle1CTD•Nup42GBM proteins and wild-type (Figure 4). 
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Figure 1. Steady-state ATPase activity of DDX19. (a) Steady state colorimetric ATPase 
assay with S. cerevisiae Dbp5 performed at 30°C and 37°C with either purified S. cerevisiae 
Gle1CTD or Gle1CTD•Nup42GBM. Reactions were performed with 0.5 µM Dbp5, 1.0 µM 
Gle1CTD or Gle1CTD•Nup42GBM, 0.1 mg/ml polyA RNA, and 2.0 µM IP6. Values shown are 
the average of three experiments. Error bars indicate the standard deviation. (b) Steady state 
colorimetric ATPase assay with H. sapiens DDX19 performed at 30 °C and 37 °C with either 
purified H. sapiens Gle1CTD or Gle1CTD•Nup42GBM. Reactions were performed with 2.5 µM 
DDX19, 5.0 µM Gle1CTD or Gle1CTD•Nup42GBM, 0.1 mg/ml polyA RNA, and 10.0 µM IP6. 
Values shown are the average of three experiments. Error bars indicate the standard 
deviation. 
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Figure 2: Human Gle1CTD activation of DDX19 is IP6 independent. Experimental data 
presented in panels d and g of this figure have been conducted by A.R.C. (a) IP6 dependence 
of S. cerevisiae performed at 30 °C with purified S. cerevisiae Gle1CTD•Nup42GBM. Reactions 
were performed with 0.5 µM Dbp5, 1.0 µM Gle1CTD•Nup42GBM, 0.1 mg/ml polyA RNA, and 
the indicated amounts of IP6. Values shown are the average of three experiments. Error bars 
indicate the standard deviation. (b) IP6 dependence of H. sapiens DDX19 activation 
performed at 37 °C with purified H. sapiens Gle1CTD•Nup42GBM. Reactions were performed 
with 2.5 µM DDX19, 5.0 µM Gle1CTD•Nup42GBM, 0.1 mg/ml polyA RNA, and the indicated 
amounts of IP6. Values shown are the average of three experiments. Error bars indicate the 
standard deviation. (c-e) Zoom view of the IP6 binding pocket of (c) S. cerevisiae, (d) 
C. thermophilum, and (e) H. sapiens Gle1CTD. Residues that are conserved in fungi but not 
metazoans are highlighted in red. (f-h) Surface electrostatic potential analysis of IP6 binding 
pockets for (f) S. cerevisiae, (g) C. thermophilum, and (g) H. sapiens Gle1. The same view 
as (c-e) is shown in surface representation colored by electrostatic potential, from red (-10 
kBT/e) to white (0 kBT/e) to blue (+10 kBT/e), revealing a dramatically reduced electrostatic 
potential for human Gle1CTD. 
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Figure 3. Biochemical analysis of DDX19 auto-inhibition and Nup214-mediated 
stimulation. (a) Schematics of the construct boundaries of DDX19 variants used in steady-
state ATPase assays. (b) Steady-state ATPase activity of DDX19 variants in the presence 
and absence of RNA, Gle1CTD•Nup42GBM, and Nup214NTD. Values reported are the average 
of three experiments. Error bars represent standard deviation. (c) Analysis of concentration 
dependence of Nup214NTD on DDX19 stimulation in the presence of RNA and 
Gle1CTD•Nup42GBM. 
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Figure 4. Effects of disease mutations on DDX19 ATPase activity. (a) Mapping single 
amino acid substitutions associated with human diseases LCCS1/LAAHD and ALS onto the 
structure of Gle1CTD•Nup42GBM•DDX19∆N53(ADP). Coloring is the same as in Figure S7a. 
(b) Steady-state ATPase activity of DDX19 stimulation by Gle1CTD variants containing 
single amino acid substitutions associated with human disease. All reported values are the 
average of three experiments. Error bars indicate standard deviation.  
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C h a p t e r  3  
IN VITRO TRANSCRIPTION AND PURIFICATION OF CTE-RNA 
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Introduction  
In eukaryotic cells, mRNA is synthesized in the nucleus from DNA, where the process is 
spatially separated from translation by ribosomes in the cytoplasm (Hoelz et al., 2011). After 
post-translational processing such as splicing and addition of a poly(A)+ tail, the mature 
mRNA is packaged with proteins into an export-competent messenger ribonucleoprotein 
(mRNP) complex (Stewart, 2010). Export serves as a checkpoint to ensure RNA fidelity; 
because only fully processed RNAs should be exported, the cell must have mechanisms to 
prevent the premature export of unprocessed mRNPs (Grüter, 1998). For example, the 
binding of splicing factors to the mRNP prevents export, sequestering it until splicing is 
completed (Legrain and Rosbash, 1989). Thus, the removal of specific retention factors that 
associate with mRNPs facilitates translocation through the NPC. One such export factor that 
mediates the passage of the mRNP through the NPC is the heterodimeric export factor 
NXF1•NXT1, which interacts with and shuttles the mRNP through the phenylalanine-
glycine (FG) repeats that compose the NPC diffusion barrier (Grüter, 1998; Katahira et al., 
1999). At the cytoplasmic face of the NPC, the mRNP encounters the DDX19 export 
machinery that facilitates specific removal of NXF1•NXT1 and release of the mRNA into 
the cytoplasm. Removal of NXF1•NXT1 guides unidirectional passage, ensuring the mRNA 
cannot re-enter through the diffusion barrier (Lund and Guthrie, 2005). Whereas the main 
steps in how the NPC regulates mRNA export by DDX19 activation are well characterized, 
as presented earlier in this text, the precise mechanism for removal of NXF1•NXT1 from the 
mRNP by DDX19 remains to be determined. 
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NXF1•NXT1 has been studied fairly extensively, along with its yeast homolog 
Mex67•Mtr2. NXF1•NXT1 is believed to serve as one of the last checkpoints to create an 
export-competent mRNP, and specific adaptor proteins are required to load the complex on 
to a processed transcript before it can be translocated. The precise mechanism by which 
NXF1•NXT1 can recognize the mature transcripts is unclear, although it is thought that the 
adaptor proteins remodel the mRNP to facilitate NXF1•NXT1 association (Stewart, 2010).  
While NXF1•NXT1 is an important factor in bulk mRNA export, it is also utilized 
by unspliced retroviral RNA. Retroviral replication depends on the export of viral RNAs, 
which can be incompletely spliced or unspliced, to encode viral proteins and to serve as the 
genomic RNA for virions assembling from the cytoplasm. Thus, viral RNA must have 
evolved methods of bypassing the standard cell checkpoints designed to block export of 
unspliced transcripts. Complex retroviruses, such as HIV, encode the viral Rev protein with 
a conventionally spliced transcript. The Rev protein can then interact with the Rev 
recognition element (RRE) sequence of unspliced RNAs encoded by the viral late genes and 
facilitate nuclear export via the Rev-NES pathway (Fischer, 1995; Hope, 1997). On the other 
hand, simple retroviruses do not express the Rev protein. Instead, simple retroviruses have a 
cis-acting RNA element, the constitutive transport element (CTE), at the 3’ end of their single 
stranded RNA genome that allows direct binding to NXF1•NXT1 without the adaptor 
proteins required for bulk mRNA export. Thus, by hijacking the NXF1•NXT1, the viral 
RNA can bypass the earlier fidelity checks and successfully translocate out of the NPC. This 
CTE is analogous in function to the RRE, but it uses cellular factors and the bulk mRNA 
export pathway, instead of Rev and the CRM1 export pathway. The CTE, identified in 
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Simian type-D retroviruses, is a ~130 nucleotide long element that forms a twofold 
symmetric RNA stem-loop motif (Hope, 1997; Grüter et al., 1998; Aibara et al., 2015). 
In the current literature, there are several crystal structures of most domains of 
NXF1•NXT1, including a structure of NXF1 bound to one symmetrical half of the CTE-
RNA (Aibara et al., 2015; Teplova et al., 2011). An atomic-resolution structure of the CTE-
bound heterodimer will provide a framework for understanding how NXF1•NXT1 interacts 
with RNA and is a starting point for further studies in whether CTE-RNA also utilizes the 
DDX19 machinery and in how DDX19 specifically remodels RNA structure. Here, we 
describe a method for large-scale synthesis and purification of CTE-RNA for 
crystallography. 
 
Development of an in vitro transcription protocol for CTE-RNA 
To study the interaction between CTE-RNA and NXF1•NXT1, a purification protocol for 
the CTE is required. Five versions of the CTE were generated: CTE FL is 125 nt long and 
contains the full extended stem-loop, and the truncation constructs remove bases in a 
symmetric manner at the opposite end of the hairpin. CTE V1 is 87 nt long, CTE V3 is 77 nt 
long, CTE ½ is 63 nt long, and CTE ½-2 is 61 nt long (one nucleotide removed at either end 
of CTE ½). The transcription template also contains cis-acting ribozymes to ensure specific 
cleavage of the 5’ and 3’ ends of the CTE, with a hammerhead (HH) ribozyme (57 nt) 
flanking the 5’ end, and a Hepatitis Delta Virus (HDV) ribozyme (85 nt) flanking the 3’ end. 
Purified CTE transcripts were desired, so a method of purification to remove the ribozymes 
was developed. Due to the similarities in size of the ribozymes and some CTE constructs, 
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additional constructs were developed to contain loop structures in the ribozymes. These loops 
did not affect catalysis, but they increased the ribozyme sizes to allow for better separation 
of the CTEs. Constructs are summarized in Table S3  
Initial tests of CTE transcription yielded incompletely cleaved transcripts. The 
hammerhead ribozyme appeared to cleave inefficiently, and the desired CTE transcript was 
not obtained (Figure 1b, lane 1). In previous work, it has been shown that the HH ribozyme 
requires at least 5 additional nucleotides complementary to the target, 5’ to the first 
catalytically required sequence (CUGA), to hybridize with the target RNA for cleavage 
(Price et al., 1995; Ferré-D’Amaré and Doudna, 1996) (Figure 1a). The existing CTE 
constructs were mutagenized with a 6-nt insertion of the required complementary bases in 
the HH sequence and transcribed again, this time observing the presence of the fully-cleaved 
CTE transcript (Figure 1b, lane 2). An additional thermocycling step post-transcription, as 
described by Lustig et al. (1995), additionally improved ribozyme efficiency, evidenced by 
the disappearance of the HH-CTE-HDV transcript (Figure 1b, lane 3). Transcripts were 
obtained for all CTE constructs, with the exception of the CTE ½-2 (Figure 1c). 
 
Scaling of CTE-RNA purification for crystallography 
For crystallization trials, milligrams of pure RNA are required. The transcription reaction 
can be easily scaled up to a greater volume, and thus a greater yield of products, but a large 
scale purification method remains challenging. The traditional method of RNA preparation 
for biochemical analyses (which typically require only microgram quantities of RNA) 
involves loading the transcription reaction mixture on a (40 x 60 x 0.3 cm) preparative 
polyacrylamide slab gel, and extracting the RNA from gel slices physically cut from the gel 
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(Heus et al., 1990; Cunningham et al., 1996). This method is both inefficient and limited in 
resolution of specific RNA products, so a method described by Cunningham et al. (1996) 
was modified for large-scale purification of the CTE transcripts for crystallography. 
Adapting a Model 491 Prep Cell (BioRad), the RNA transcription mixture was 
loaded on a cylindrical polyacrylamide gel, which was continuously electrophoresed as a 
peristaltic pump ran elution buffer over the gel, through a UV-vis detector, and into fractions. 
An ÄKTA Start Protein Purification System (GE Healthcare) was adapted to connect to the 
Model 491 Prep Cell, serving as the peristaltic pump, detecting the UV-260 trace, and 
collecting fractions. An initial test run of this method was conducted with a 1 ml transcription 
reaction containing the CTE FL construct. The elution was performed at a conservative 0.5 
ml/min, compared to the 1 ml/min described by Cunningham et al. (1996), on a native 8% 
TBE polyacrylamide gel. The system ran for 20 hours, yielding separation shown in 
Figure 1d.  
From this initial test, several observations were made. (1) The CTE FL construct was 
too close in size to the HDV ribozyme, so the resolution of the gel was not high enough to 
obtain pure CTE FL (Figure 1d, red box). (2) The extended length of time required to run the 
system resulted in additional ribozyme cleavage of initially uncleaved transcripts occurring 
as the transcription reaction moved through the gel. Evidence of this additional cleavage is 
observed the later lanes of Figure 1d where additional HH ribozyme elutes after the larger 
HDV and CTE transcripts. (3) A transcript the size of the HH ribozyme is separable and 
relatively pure in the early elution fractions (Figure 1d), which suggests that the CTE ½ 
construct is a promising target, especially with the looped HH construct isolating the CTE ½ 
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further (magenta boxes in Figure 1c). With this method to increase the scale of RNA 
purification, enough pure CTE-RNA can be obtained for X-ray crystallography studies. 
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Figure 1. Scaling in vitro transcription for crystallization trials. (a) Schematic of 
hammerhead ribozyme cleavage structure. Highlighted regions are sequences required for 
efficient cleavage. The cleavage site is marked with an arrow, and the red sequence indicates 
the 6-nt insertion complementary to the target sequence. The 5’-end additionally contains the 
T7 RNA polymerase promoter sequence, and the 3’-end contains the remainder of the CTE 
sequence and Hepatitis Delta Virus ribozyme. The CTE sequence shown is CTE V3. (*) 
denotes length before 6-nt insertion. (b) Comparison of in vitro transcription products (1) 
without the 6-nt insertion, (2) with the 6-nt insertion, and (3) with an additional thermal 
cycling step. Transcription reactions were visualized with ethidium bromide stained 
10% denaturing Urea PAGE gels. (c) Transcription products of all CTE versions, visualized 
with ethidium bromide stained 12% native PAGE and 8% denaturing Urea PAGE gels. 
Bands corresponding to the ribozyme-cleaved CTE products are highlighted in colored 
boxes. (d) Fractions eluted from 8% native PAGE gel cast in a Model 491 BioRad Prep Cell 
37 mm chamber. RNA was visualized with SYBR Gold stained 8% denaturing Urea PAGE 
gels. The desired CTE product is highlighted with a red box. 
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CONCLUSION 
Here we have presented a structural and functional analysis of mRNA export regulation by 
the NPC. First, we show that the interaction between Gle1CTD and Nup42GBM is highly 
conserved with atomic resolution X-ray crystal structures of the complex from three separate 
species. The hydrophobic interaction interface revealed by the structures provides a chemical 
explanation for how Nup42CTD drastically alters Gle1CTD thermostability and, in cells, 
stabilizes Gle1 at the NPC during heat shock. Clearly, Nup42 plays a large role in 
maintaining the proper fold of Gle1CTD, which also explains its apparent effect on DDX19 
activation. Rather than directly stimulating DDX19, Nup42GBM allosterically activates the 
enzyme by ensuring the stability of Gle1CTD. Interestingly, variants of Gle1CTD with point 
mutations linked to the motor neuron diseases LAAHD and LCCS1 display altered 
thermostability. Misfolded Gle1 would likely impair the mRNA export cycle, and our results 
provide a framework for further studies in understanding the molecular basis of human 
disease linked to Gle1. 
We also present the reconstitution of fully stimulated human DDX19, in vitro. The 
biochemistry described here supplements a comprehensive set of X-ray crystal structures 
displaying the various activation states of DDX19. From these analyses, we found several 
striking differences between the metazoan and fungal machinery, where in humans, Gle1-
mediated DDX19 activation is IP6 independent and largely relies on Gle1-mediated removal 
of an auto-inhibitory helix. From a comparison of apo DDX19∆N53 and Gle1CTD•Nup42GBM• 
DDX19∆N53, we have elucidated the precise molecular mechanism of how Gle1CTD activates 
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the enzyme. By studying the ATPase activity of DDX19 variants mutated in the N-terminal 
auto-inhibitory helix, we show that Gle1CTD stimulates DDX19 via relief of auto-inhibition. 
With these results, we propose a new working model of mRNA export by the nuclear pore 
complex (Figure 1). In our model, DDX19 remains predominantly in a closed state with the 
auto-inhibitory helix tightly bound, but Gle1 (stabilized by Nup42) can open the enzyme for 
nucleotide exchange. Here, Nup214 can further accelerate this process. The ATP bound 
enzyme can then cycle between open and closed states until it encounters NXF1•NXT1 
bound mRNA, where DDX19 then displaces the export factor and hydrolyzes ATP to release 
mRNA and start a new cycle.  
One outstanding question not answered by our model is how DDX19 specifically 
remodels the NXF1•NXT1-bound mRNP to dissociate the export factors. One hypothesis 
suggests that RNA is forced into a specific secondary structure by adaptor proteins in the 
nucleus, and this structure is recognized by NXF1•NXT1. When DDX19 contacts the RNA, 
it may remodel the RNA such that the NXF1•NXT1-compatible structure is removed, 
thereby removing the NXF1•NXT1. However, this will remain only a hypothesis until 
further studies of the specific interactions between NXF1•NXT1, RNA, and DDX19 are 
conducted. Some clues may come from the study of the retroviral CTE-RNA, which is 
sufficient to interact with NXF1•NXT1 and hijack the bulk mRNA export pathway. We 
presented a method to synthesize and purify crystallographic quantities of CTE-RNA. With 
the construct boundaries from a preliminary X-ray crystal structure of NXF1•NXT1•CTE ½, 
future work would center on obtaining an atomic-resolution structure of the complex and on 
investigating the interplay between NXF1•NXT1, CTE/bulk mRNA, and DDX19. 
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Figure 1. Proposed working model for DDX19 catalytic cycle. (a) Schematic cartoon of 
the DDX19 catalytic cycle. (b) Schematic of the DDX19 catalytic cycle with crystal 
structures of each state. The inhibited conformation corresponds to the crystal structure of 
DDX19∆N53(ADP) (PDB ID 3EWS) (Collins et al., 2009). The closed Gle1-bound 
conformations correspond to the crystal structures of Gle1CTD•Nup42GBM•DDX19∆N53(AMP-
PNP•Mg2+) and Gle1CTD•Nup42GBM•DDX19∆N53(ADP). The Gle1-bound open 
conformations correspond to the yeast Gle1CTD•IP6•Dbp5∆N90(ADP) and 
Gle1CTD•IP6•Dbp5∆N90(ADP)•Nup159NTD (PDB IDs 3RRM and 3RRN) (Montpetit et al., 
2011). The RNA bound conformation corresponds to the crystal structure of 
DDX19∆N53(AMP-PNP•Mg2+)•U10 RNA (PDB ID 3G0H) (Collins et al., 2009). 
Gle1CTD•Nup42GBM and Nup214NTD correspond to the apo structures (PDB ID 2OIT) 
(Napetschnig et al., 2009). (Adapted from Lin et al., 2018) 
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MATERIALS AND METHODS 
Construct generation. DNA fragments were amplified using the polymerase chain reaction. 
SUMO-tagged proteins were cloned into a modified pET28a vector (Mossessova and Lima, 
2000). GST-tagged proteins were cloned into a pGEX-6P-1 vector. His6-tagged proteins 
were cloned into a modified pET28a vector (Hoelz et al., 2003). S. cerevisiae and H. sapiens 
Gle1CTD•Nup42GBM were cloned into a modified pETDuet-1 vector with Nup42GBM in the 
first site and Gle1CTD in the second site (Stuwe et al., 2015). Mutants were generated using 
the QuikChange mutagenesis protocol and confirmed by DNA sequencing. Details of 
bacterial expression constructs and expression conditions are shown in 
Supplementary Table 1. 
 
Protein expression and purification. Proteins were expressed in E. coli BL21-
CodonPlus(DE3)-RIL cells (Stratagene) in Luria-Bertani media and induced at an OD600 of 
~0.6 with 0.5 mM IPTG (Gold Biotechnology). Chemicals were purchased from Sigma 
unless otherwise noted. Unless otherwise noted, cells were harvested by centrifugation and 
resuspended in a buffer containing 20 mM TRIS (pH 8.0), 500 mM NaCl, 4 mM 2-
mercaptoethanol (β-ME), and 15 mM imidazole, supplemented with complete EDTA-free 
protease inhibitor cocktail (Roche) and flash frozen in liquid nitrogen. Cells were 
supplemented with 1 mg deoxyribonuclease I (Roche), lysed with a cell disruptor (Avestin), 
and centrifuged at 4 °C and 30,000 g for 1 hour. Supernatants were loaded onto a Ni-NTA 
affinity column (GE Healthcare) equilibrated in a buffer containing 20 mM TRIS (pH 8.0), 
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500 mM NaCl, 4 mM β-ME, and 15 mM imidazole and eluted with a linear gradient of 
imidazole concentration to 500 mM. Eluted proteins were dialyzed overnight with a buffer 
containing 20 mM TRIS (pH 8.0), 100 mM NaCl, 4 mM β-ME, and 15 mM imidazole and 
subsequently purified through affinity, ion exchange, and size exclusion chromatography. 
hsGle1CTD•His6-hsNup42GBM variants, scGle1CTD•His6-scNup42GBM, and His6-
scGle1CTD were grown for 18 hours at 18 °C. His6-ctGle1CTD was co-expressed with GST-
ctNup42GBM and grown for 3 hours at 37 °C. After elution from the Ni-NTA column, the 
His6 tag and the GST tag were removed by cleavage with PreScission protease concurrent 
with dialysis. Dialyzed protein was loaded onto a Ni-NTA column equilibrated in a buffer 
containing 20 mM TRIS (pH 8.0), 100 mM NaCl, 4 mM β-ME, and 15 mM imidazole. 
Protein-containing fractions were pooled and loaded onto a HiTrap Heparin HP column (GE 
Healthcare) equilibrated in a buffer containing 20 mM TRIS (pH 8.0), 100 mM NaCl, and 
5 mM dithiothreitol (DTT) and eluted with a linear gradient of NaCl concentration to 2 M. 
Protein-containing fractions were concentrated and loaded onto a HiLoad Superdex 75 16/60 
PG column (GE Healthcare) equilibrated in a buffer containing 20 mM TRIS (pH 8.0), 
100 mM NaCl, and 5 mM DTT. 
His6-SUMO-hsGle1CTD was grown for 18 hours at 18 °C and purified as 
hsGle1CTD•His6-hsNup42GBM, except the His6-SUMO tag was removed by Ulp1 cleavage. 
His6-hsDDX19 variants, His6-scDbp5 and His6-SUMO-ctDbp5 were grown for 
18 hours at 18 °C. Cells were harvested by centrifugation and resuspended in a buffer 
containing 20 mM TRIS (pH 8.0), 500 mM NaCl, 4 mM β-ME, 15 mM imidazole, and 5 % 
(v/v) glycerol, supplemented with Complete EDTA-free protease inhibitor cocktail (Roche) 
and flash frozen in liquid nitrogen. After lysis and centrifugation, the supernatant was loaded 
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onto a Ni-NTA column equilibrated in a buffer containing 20 mM TRIS (pH 8.0), 500 mM 
NaCl, 4 mM β-ME, 15 mM imidazole, and 5 % (v/v) glycerol. Protein was eluted with a 
linear gradient of imidazole concentration to 500 mM and protein-containing fractions were 
dialyzed overnight in a buffer containing 20 mM TRIS (pH 8.0), 100 mM NaCl, 4 mM β-
ME, 15 mM imidazole, and 5 % (v/v) glycerol. The His6 tags of His6-DDX19 variants and 
His6-scDbp5 were cleaved using PreScission protease concurrent with overnight dialysis. 
The His6-SUMO tag of His6-SUMO-ctDbp5 was cleaved with Ulp1 protease and the cleaved 
protein was desalted with dialysis buffer immediately after elution from the Ni-NTA column. 
The dialyzed/desalted protein was loaded onto a Ni-NTA column equilibrated in a buffer 
containing 20 mM TRIS (pH 8.0), 100 mM NaCl, 4 mM β-ME, 15 mM imidazole, and 5 % 
(v/v) glycerol. Protein-containing flowthrough fractions were loaded onto a HiTrap Q HP 
column (GE Healthcare) equilibrated in a buffer containing 20 mM TRIS (pH 8.0), 100 mM 
NaCl, 5 mM DTT, and 5 % (v/v) glycerol and eluted with a linear gradient of NaCl 
concentration to 2 M. Protein-containing fractions were concentrated and loaded onto a 
HiLoad Superdex 200 16/60 PG column (GE Healthcare) equilibrated in a buffer containing 
20 mM TRIS (pH 8.0), 100 mM NaCl, 5 mM DTT, and 5 % (v/v) glycerol. 
His6-SUMO-hsGle1N and variants were grown at 30 °C for 2 hours after IPTG 
induction. After elution from the Ni-NTA column, proteins were dialyzed overnight in a 
buffer containing 20 mM TRIS (pH 8.0), 100 mM NaCl, and 5 mM DTT. After dialysis, 
proteins were loaded onto a HiTrap Q HP column and eluted with a linear gradient of NaCl 
concentration to 2 M. Protein containing fractions were concentrated and loaded onto a 
Superdex 200 10/300 GL column (GE Healthcare) equilibrated in a buffer containing 20 mM 
TRIS (pH 8.0), 100 mM NaCl, and 5 mM DTT. 
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His6-SUMO-scNup42GBM-His6 and variants were grown at 37 °C for 2 hours after 
IPTG induction. After elution from the Ni-NTA column, the His6-SUMO tag was removed 
by cleavage with Ulp1 concurrent with overnight dialysis into a buffer containing 20 mM 
TRIS (pH 8.0), 100 mM NaCl, and 5 mM DTT. After dialysis, proteins were injected onto a 
HiTrap Q HP column and collected in the flowthrough. Protein-containing fractions were 
concentrated and loaded onto a Superdex Peptide 10/300 GL column (GE Healthcare). 
His6-Nup214NTD was grown for 18 hours at 18 °C after IPTG induction. After elution 
from the Ni-NTA column, the protein was dialyzed overnight in 20 mM TRIS (pH 8.0), 
500 mM NaCl, 4 mM β-ME, and 15 mM imidazole. The His6 tag was removed by cleavage 
with PreScission protease concurrent with dialysis. Dialyzed protein was loaded onto a Ni-
NTA column equilibrated in a buffer containing 20 mM TRIS (pH 8.0), 100 mM NaCl, 4 mM 
β-ME, and 15 mM imidazole. Protein-containing fractions were pooled and loaded onto a 
HiTrap Q HP column equilibrated in a buffer containing 20 mM TRIS (pH 8.0), 100 mM 
NaCl, and 5 mM DTT and eluted with a linear gradient of NaCl concentration to 2 M. 
Protein-containing fractions were concentrated and loaded onto a HiLoad Superdex 200 
16/60 PG column equilibrated in a buffer containing 20 mM TRIS (pH 8.0), 100 mM NaCl, 
and 5 mM DTT. 
 
Crystallization and structure determination. S. cerevisiae Gle1CTD•Nup42GBM was 
crystallized at 23 °C with the hanging drop method using 1 µl of protein solution 
(22.5 mg/ml) and 1 µl of reservoir solution, containing 0.1 M HEPES (pH 8.2) (Sigma), 11 % 
(w/v) PEG 3,350, and 0.2 M L-Proline. Crystals were cryoprotected with a solution identical 
to the reservoir solution, but supplemented with 30 % (v/v) ethylene glycol. X-ray diffraction 
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data were collected at beamline 12-2 at the Stanford Synchotron Radiation Lightsource 
(SSRL) and processed with the XDS package (Kabsch, 2010). The structure was solved by 
molecular replacement with Phaser, using the structure of Gle1CTD (PDB ID 3RRN) as a 
search model (Montepetit et al., 2011; McCoy et al., 2007). The structure was refined using 
the PHENIX package with TLS refinement (Adams et al., 2010). One of the Gle1 molecules 
in the asymmetric unit displays two distinct conformations for half the molecule and was 
modeled as two alternate conformations for the entire residue range. The final structure was 
refined to Rwork and Rfree values of 18.5 % and 21.1 %, respectively, with excellent geometry 
(MolProbity score 0.96) (Chen et al., 2010). 
H. sapiens Gle1CTD•Nup42GBM was crystallized at 23 °C with the hanging drop 
method using 1 µl of protein solution (20 mg/ml) and 1 µl of reservoir solution, containing 
0.2 M sodium potassium phosphate (pH 7.6) and 26 % (w/v) PEG 3,350. Crystals were 
cryoprotected by gradual supplementation of ethylene glycol in 5 % steps to a final 
concentration of 30 % (v/v). X-ray diffraction data were collected at beamline 23-ID-D at 
the Advanced Photon Source (APS) and processed with the XDS package (Kabsch, 2010). 
The diffraction data was anisotropic, with diffraction limits along the three principal 
components of 2.8 Å, 3.1 Å, and 3.1 Å. The structure was solved by molecular replacement 
with Phaser, using the structure of S. cerevisiae Gle1CTD (PDB ID 3RRN) as a search model 
(Montpetit et al., 2011; McCoy et al., 2007). Refinement was performed using torsion NCS 
restraints with the PHENIX package using anisotropically truncated and scaled data 
generated using the UCLA-DOE anisotropy server (Adams et al., 2010, Strong et al., 2006). 
The final structure was refined to Rwork and Rfree values of 24.5 % and 27.4 %, respectively, 
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with excellent geometry (MolProbity score 1.31) (Chen et al., 2010). For details of the data 
collection and refinement statistics, see Supplementary Table 1. 
 
Yeast strain generation. The nup42∆/gle1-GFP strain was generated in a BY4741 parental 
strain by first introducing the natNT2 cassette by homologous recombination into the nup42 
gene followed by three rounds of selection on yeast extract peptone dextrose (YPD) plates 
containing Nourseothricin (Gold Biotechnology) (Janke et al., 2004). Subsequently, a GFP-
kanMX cassette was inserted into the C-terminus of Gle1 followed by three rounds of 
selection on YPD plates containing G418 (Janke et al., 2004). Nup42-mCherry variants were 
introduced using a modified pRS415 plasmid followed by two rounds of selection on plates 
containing leucine-depleted synthetic dextrose complete medium (SDC-LEU). For details of 
yeast strains and constructs, see Supplementary Table 3. 
 
Yeast live cell fluorescence. Cells were grown in SDC-LEU medium to mid-log phase at 
30 ºC and shifted to 42 ºC for 3 hours. For fluorescence imaging, cells were pelleted by 
centrifugation for 2 minutes at 650 g, resuspended in water, and imaged using a Carl Zeiss 
Observer Z.1 equipped with a Hamamatsu camera C10600 Orca-R2. 
 
Yeast growth assay. For growth analysis, cells were grown in SDC-LEU medium at 30 ºC 
to an OD600 of 0.2. 15 µl of a ten-fold dilution series was spotted onto plates containing SDC-
LEU medium, which were incubated at 30 ºC and 37 ºC. 
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GST pull-down interaction analysis: Interaction studies with GST-Nup42 and His6-Gle1 
were performed using GST pull-down experiments. Approximately 100 µl of a 50% (v/v) 
slurry of glutathione-coupled sepharose beads (GE Healthcare) were equilibrated with a 
buffer containing 20 mM TRIS (pH 8.0), 100 mM NaCl, and 5 mM DTT. The equilibrated 
resin was incubated with cleared and filtered lysate from 1 L of bacterial expression culture. 
The resin was washed 3x with the equilibration buffer (15 ml) and centrifuged with 500 x g 
at 4°C. Bound protein was eluted from the beads with 250 µl of the wash buffer supplemented 
with 25 mM reduced glutathione. Eluted protein was resolved by SDS-PAGE and visualized 
by Coomassie brilliant blue staining. 
 
Differential scanning fluorimetry assay. Differential scanning fluorimetry was performed 
using a previously described protocol (Niesen et al., 2007). Using a real-time PCR instrument 
(Bio-Rad C1000 96 well Thermal Cycler), fluorescence of a 20 µl mixture of 5 µM purified 
protein and 5x SYPRO orange dye (Invitrogen) was measured once per minute while the 
temperature was increased 1 °C/min from 4 °C to 95 °C. Reactions were performed in 20 mM 
TRIS (pH 8.0), 100 mM NaCl, and 5 mM DTT. When present, IP6 was supplemented to 
25 µM for yeast proteins and 100 µM for human proteins. The reported Tm values were 
determined by finding the temperature corresponding to the maximum of the first derivative 
of the thermal melting curve. Traces represent the average of three experiments. 
 
Pelleting thermostability assay. 50 µl samples of purified protein (10 µg each) were 
incubated for 30 minutes at indicated temperatures between 25 °C and 55 °C. Soluble and 
pellet fractions were isolated by centrifugation at 30,000 g for 35 minutes at 4 °C. Reactions 
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were performed in a buffer containing 20 mM TRIS (pH 8.0), 100 mM NaCl, and 5 mM 
DTT. When present, IP6 was added to a final concentration of 20 µM. Proteins were resolved 
by SDS-PAGE gel and visualized with Coomassie brilliant blue staining. 
 
NADH-coupled ATPase assay. Steady-state ATPase activity rates were determined at 
30 °C and 37 °C for scDbp5 and hsDDX19 using previously established conditions 
(Montpetit et al., 2012). The reaction mixture (80 µl) contained purified scDbp5 and 
hsDDX19 (WT and variants) at 0.5 µM and 2.5 µM, respectively. Unless otherwise noted, 
all other S. cerevisiae and H. sapiens proteins (Gle1CTD, Gle1CTD•Nup42GBM, or Nup214NTD) 
were present at concentrations of 1 µM and 5 µM, respectively. When present, polyA RNA 
with length ranging between 465 and 660 bases (GE Healthcare, 27411001) was added to a 
final concentration of 0.1 mg/ml. When present, IP6 was supplemented to a final 
concentration of 2 µM and 10 µM for yeast and human, respectively, unless otherwise noted. 
The reaction mixture contained 30 mM HEPES (pH 7.5), 100 mM NaCl, 2 mM MgCl2, 
1 mM DTT, 6 mM phosphoenolpyruvate (PEP, Alfa Aesar), 1.2 mM NADH (Sigma), 1.6 µl 
pyruvate kinase (PK)/lactate dehydrogenase enzyme solution (LDH) (Sigma), and 2.5 mM 
ATP (Sigma), unless otherwise noted. 
For each reaction, two separate mixtures were prepared and kept separate until 
initiation of the reaction. The first mixture, containing the protein components, IP6, polyA 
RNA, and buffer (HEPES, NaCl, and MgCl2), was prepared to a final volume of 20 µl and 
incubated on ice. The second mixture, containing buffer, DTT, PEP, NADH, ATP, and 
PK/LDH, was prepared to a final volume of 60 µl and dispensed into a 96-well plate. 
Reactions were initiated by addition of the protein mixture. Plates were centrifuged at 4,000 g 
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for 2 minutes at 4 °C prior to being loaded in the pre-warmed plate reader. A340 was measured 
every 30 seconds for 30 minutes using a FlexStation 3 microplate reader (Molecular 
Devices). Rates were calculated by fitting the linear portion of the reaction. Reported rates 
were determined by dividing the rate of ATP consumption by the concentration of 
DDX19/Dbp5 in the reaction. All values reported are the average of three experiments. 
 
RNA Template Generation. CTE constructs were cloned into a modified puc19 vector, 
flanked by a 5’ Hammerhead (HH) ribozyme sequence and a 3’ Hepatitis Delta Virus (HDV) 
ribozyme sequence. Insertions of the 6-nt HH hybridization region were generated using the 
QuikChange mutagenesis protocol and confirmed by DNA sequencing. Plasmids were 
digested at 37°C for 16 hours with XbaI and concentrated by ethanol precipitation. 
Constructs are summarized in Table S3. 
 
In vitro RNA transcription. Transcription reactions (100 µl) contained 10 µl 10x T7 
transcription buffer, 3 µl 1 M NaOH, 30 µl rNTPs, 5 µg template DNA, 0.4 µl Superase In, 
0.25 µl inorganic phosphatase, 5 µl T7 RNA polymerase, and Milli Q water to volume. 
Reactions were incubated at 37 °C for 4 hours, followed by thermal cycling as previously 
described (Lustig et al., 1995) and quenching with 2x RNA loading dye. The products were 
visualized using native TBE-PAGE and denaturing Urea-PAGE and stained with ethidium 
bromide or SYBR Gold where indicated.  
 
RNA purification. CTE-RNAs were separated on a (40 x 60 x 0.3 cm) preparative Urea-
PAGE slab gel, excised after UV-shadowing, and phenol chloroform extracted. For the large-
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scale preparation, the transcription reaction mixture was loaded onto a Model 491 Prep Cell 
(BioRad) 37 mm native TBE-PAGE gel cylinder and electrophoresed. RNA was visualized 
by UV-detection and fractionated on an ÄKTA-Start. Purified RNAs were visualized using 
denaturing Urea-PAGE and stained with ethidium bromide or SYBR Gold where indicated. 
 
Illustrations and figures. All structural figures and movies were ray traced in PyMol 
(Schrödinger). Surface electrostatic potential plots were calculated using Adaptive Poisson-
Boltzmann Solver (APBS) (Baker et al., 2001). Secondary structure predictions were 
generated with the PSIPRED server (Buchan et al., 2013). Sequence alignments were 
generated using MUSCLE and visualized with ALSCRIPT (Barton, 1993; Edgar, 2004). 
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APPENDIX 
 
Figure S1. Mapping the minimal Gle1CTD binding region on Nup42. GST-tagged Nup42 
fragments and SUMO-tagged Gle1CTD were overexpressed in bacterial culture, and GST-
Nup42 was used to pull down SUMO-Gle1CTD on GST resin. (*) indicates crystallized 
construct. (a) H. sapiens Nup42 construct boundaries and pull-down. (b) S. cerevisiae Nup42 
construct boundaries and pull-down. 
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Figure S2. In vivo analysis of Nup42GBM and Gle1 heat shock phenotypes. (a) In vivo 
localization analysis in S. cerevisiae of Gle1-GFP and Nup42-mCherry variants. Scale bar 
length is 5 µm. Schematics to the right indicated the fragments of Nup42 that were included 
in the construct, with omitted fragments indicated by replacement of the domain with a solid 
line. Residue numbers indicate the fragment included in each construct. (b) Growth analysis 
of S. cerevisiae strains containing the indicated Nup42-mCherry variants. 10-fold serial 
dilutions were spotted onto SDC-LEU plates and grown for 4 days at 30 and 37°C. 
Constructs are the same as schematized above.  
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Figure S3. Multispecies sequence alignment of Gle1CTD. This analysis was generated by 
D.H.L. Sequences from fourteen diverse species were aligned and colored by sequence 
similarity according to the BLOSUM62 matrix from white (less than 40% similarity), to 
yellow (55% similarity), to red (100% identity). The numbering is according to the H. 
sapiens protein. The secondary structure is indicated above the sequences as rectangles (α-
helices) and lines (unstructured regions) for the S. cerevisiae, C. thermophilum, and H. 
sapiens proteins. (Adapted from Lin et al., 2018) 
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Figure S4. Steady state colorimetric ATPase activity assay controls. (a, b) SDS-PAGE 
analysis of the purified (a) yeast or (b) human proteins used in activity assays. (c) RNA 
dependence of S. cerevisiae Dbp5 activation. Reactions were performed at 30 °C and 37 °C 
with 0.5 µM Dbp5, 1.0 µM Gle1CTD or Gle1CTD•Nup42GBM, and 2.0 µM IP6, with the 
indicated amounts of RNA. Values reported are the average of three experiments. Error bars 
represent standard deviation. (d) RNA dependence of H. sapiens DDX19 activation. 
Reactions were performed at 30 °C and 37 °C with 2.5 µM DDX19, 5.0 µM Gle1CTD or 
Gle1CTD•Nup42GBM, and 10.0 µM IP6, with the indicated amounts of RNA. Values reported 
are the average of three experiments. Error bars represent standard deviation. (e) ATP 
dependence of Dbp5 activity. Values reported are the average of three experiments. Error 
bars represent standard deviation. (f) ATP dependence of DDX19 activity. Values reported 
are the average of three experiments. Error bars represent standard deviation. (g) Steady-state 
ATPase activity of a catalytically dead DDX19 mutant or a Gle1CTD mutant that abolishes 
stimulation of DDX19 by Gle1CTD, indicating that no activity can be attributed to 
contaminating factors. Values reported are the average of three experiments. Error bars 
represent standard deviation. (Adapted from Lin et al., 2018). 
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Figure S5. Multispecies sequence alignment of the Gle1 IP6 pocket and the DDX19 C-
terminal helix. This analysis was generated by D.H.L. Basic residues conserved in fungi are 
outline with black boxes. Residues are colored according to an adapted Clustal color scheme. 
(Adapted from Lin et al., 2018). 
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Figure S5. IP6 dependence of the Gle1CTD•Nup42GBM•DDX19 interaction. This 
experiment was conducted by D.H.L. (a-c) SEC analysis of the interaction between 
Dbp5/DDX19 and Gle1CTD•Nup42GBM for (a) S. cerevisiae, (b) C. thermophilum, and (c) 
H. sapiens, in the presence or absence of IP6. The elution profiles for Dbp5/DDX19 are 
shown in purple, Gle1CTD•Nup42GBM are shown in gray or orange, Dbp5/DDX19 with 
Gle1CTD•Nup42GBM and IP6 are shown in light blue, and Dbp5/DDX19 with 
Gle1CTD•Nup42GBM without IP6 are shown in black. Fungal Gle1CTD•Nup42GBM interacts 
strongly with the Superdex matrix in the absence of IP6. The gray horizontal bar indicates 
fractions visualized with Coomassie-stained SDS-PAGE gels shown below. (Adapted from 
Lin et al., 2018). 
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Figure S7. Structure of the human Gle1CTD•Nup42GBM•DDX19∆N53 complex. This 
experiment was conducted by D.H.L. and A.R.C. (a) Crystal structure of H. sapiens 
Gle1CTD•Nup42GBM•DDX19∆N53(ADP). Motifs of interest are colored and labeled: auto-
inhibitory helix (residues 54-67, purple); mobile loop (residues 68-91, blue); trigger loop 
(residues 328-335, yellow); anchor loop (residues 390-403, cyan); motif VI (residues 429-
435, light cyan); C-terminal helix (residues 468-479, magenta). Boxes indicate the regions 
shown to the right. (b, c) Close-up views of critical complex-forming interactions in 
interfaces 1 and 2. (d) Left: crystal structure of H. sapiens 
Gle1CTD•Nup42GBM•DDX19∆N53(AMP-PNP•Mg2+). DDX19 is colored magenta for clarity. 
Right: Superposition of the ADP and AMP-PNP•Mg2+ bound structures. (e) Analysis of the 
effect of single amino acid substitutions in the Gle1-DDX19 interface on Gle1-mediated 
stimulation of DDX19, using the same conditions as in Figure 1b at 37 °C. Values shown are 
the average of three experiments. Error bars indicate standard deviation. (f) Left: crystal 
structure of S. cerevisiae Gle1CTD•IP6•Dbp5∆N90(ADP) (PDB ID 3RRN) (Montpetit et al., 
2011). Right: superposition of the S. cerevisiae and H. sapiens structures. The arrow indicates 
the rotation relating the conformations observed in the two crystal structures. Circles 
highlight structural differences. (Adapted from Lin et al., 2018). 
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Figure S8: Conformational changes in DDX19 induced by Gle1 binding. This 
experiment was conducted by D.H.L. and A.R.C. (a) Left: crystal structure of H. sapiens 
DDX19∆N53(ADP) (PDB ID 3EWS) (Collins et al., 2009). Disordered regions (C-terminal 
helix and motif VI) are indicated with dashed lines. Middle: crystal structure of H. sapiens 
Gle1CTD•Nup42GBM•DDX19∆N53(ADP) shown in the same orientation and colored as in 
Figure S7a. Right: superposition of the two structures. Arrows indicate the rotation relating 
the conformations of DDX19∆N53(ADP) in the presence and absence of Gle1CTD•Nup42GBM. 
The cartoon on the right schematizes the transition from the inhibited state to the Gle1-bound 
state. (b) Zoom view of the DDX19 trigger loop (yellow) in (left) the inhibited state (PDB 
ID 3EWS), (middle) the Gle1-bound state, and (right) their superposition. The cartoon on the 
right indicates the region of DDX19 shown. (c) Zoom view of the DDX19 anchor loop (cyan) 
and auto-inhibitory helix (purple) in the (left) inhibited state (PDB ID 3EWS), (middle) the 
Gle1-bound state, and (right) their superposition. The cartoon on the right indicates the region 
of DDX19 shown. (d) Zoom view of DDX19 Motif VI in (left) the inhibited state (PDB ID 
3EWS), (middle) the Gle1-bound state, and (right) the RNA-bound state (PDB ID 3G0H) 
(Collins et al., 2009). The cartoon on the right indicates the region of DDX19 shown. 
(Adapted from Lin et al., 2018). 
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Supplementary Table 1. 
Bacterial expression constructs and expression conditions 
# 
 
Protein 
 
Residues 
 
Expression 
vector 
Restriction 
sites 5’, 3’ 
N-terminal 
overhang 
C-terminal 
overhang 
Expression 
conditions 
1 hsGle1 CTD 382-698 pET28a-SUMO BamHI, NotI Smt3p-S - 18 °C / 18 hours 
2 hsNup42 CTD (379-400) 379-400 pGex6P-1 PreS BamHI, NotI 
GST-
LEVLFQG
PHM 
- 18 °C / 18 hours 
3 hsNup42 CTD (379-405) 379-405 pGex6P-1 PreS BamHI, NotI 
GST-
LEVLFQG
PHM 
- 18 °C / 18 hours 
4 hsNup42 CTD (379-411) 379-411 pGex6P-1 PreS BamHI, NotI 
GST-
LEVLFQG
PHM 
- 18 °C / 18 hours 
5 hsNup42 CTD (379-423) 379-423 pGex6P-1 PreS BamHI, NotI 
GST-
LEVLFQG
PHM 
- 18 °C / 18 hours 
6 hsNup42 CTD (384-423) 384-423 pGex6P-1 PreS BamHI, NotI 
GST-
LEVLFQG
PHM 
- 18 °C / 18 hours 
7 hsNup42 CTD (390-423) 390-423 pGex6P-1 PreS BamHI, NotI 
GST-
LEVLFQG
PHM 
- 18 °C / 18 hours 
8 hsNup42 CTD (395-423) 395-423 pGex6P-1 PreS BamHI, NotI 
GST-
LEVLFQG
PHM 
- 18 °C / 18 hours 
9 scGle1 CTD 244-538 pET28a-SUMO BamHI, NotI Smt3p-S - 18 °C / 18 hours 
10 scNup42 CTD (381-405) 381-405 pGex6P-1 PreS BamHI, NotI 
GST-
LEVLFQG
PHM 
- 18 °C / 18 hours 
11 scNup42 CTD (381-419) 381-419 pGex6P-1 PreS BamHI, NotI 
GST-
LEVLFQG
PHM 
- 18 °C / 18 hours 
12 scNup42 CTD (381-430) 381-430 pGex6P-1 PreS BamHI, NotI 
GST-
LEVLFQG
PHM 
- 18 °C / 18 hours 
13 scNup42 CTD (391-430) 391-430 pGex6P-1 PreS BamHI, NotI 
GST-
LEVLFQG
PHM 
- 18 °C / 18 hours 
14 scNup42 CTD (397-430) 397-430 pGex6P-1 PreS BamHI, NotI 
GST-
LEVLFQG
PHM 
- 18 °C / 18 hours 
15 scGle1 CTD 244-538 pET28a-PreS NdeI, XhoI GPHM - 18 °C / 18 hours 
16t scGle1 CTD scNup42 GBM 
244-538 
397-430 
pETDuet 
PreS 
NdeI, XhoI 
BamHI, NotI 
M 
GPSGS 
- 
- 18 °C / 18 hours 
17 hsGle1 CTD 382-698 pET28a-SUMO BamHI, NotI S - 18 °C / 18 hours 
18t hsGle1 CTD hsNup42 GBM 
382-698 
379-423 
pETDuet 
PreS 
NdeI, XhoI 
BamHI, NotI 
M 
GPSGS 
- 
- 18 °C / 18 hours 
19t ctGle1 CTD 216-519 pET28a-PreS NdeI, NotI GPHM - 
37C °C / 3 hours 
co-expressed with 
ctNup42 
20t ctNup42 GBM 494-558 pGex6P-1 PreS EcoRI, XhoI 
GPHMGS
PEF - 
37C °C / 3 hours 
co-expressed with 
ctGle1 
21 scNup42 GBM 397-430 pET28a-SUMO BamHI, XhoI S 
YALEHHH
HHH 37 °C / 2 hours 
22 scNup42 GBM F409A 397-430 pET28a-SUMO BamHI, XhoI S 
YALEHHH
HHH 37 °C / 2 hours 
  75 
# 
 
Protein 
 
Residues 
 
Expression 
vector 
Restriction 
sites 5’, 3’ 
N-terminal 
overhang 
C-terminal 
overhang 
Expression 
conditions 
23 scNup42 GBM F414A 397-430 pET28a-SUMO BamHI, XhoI S 
YALEHHH
HHH 37 °C / 2 hours 
24 scNup42 GBM L416A 397-430 pET28a-SUMO BamHI, XhoI S 
YALEHHH
HHH 37 °C / 2 hours 
25 scNup42 GBM L416R 397-430 pET28a-SUMO BamHI, XhoI S 
YALEHHH
HHH 37 °C / 2 hours 
26 scNup42 GBM P423A 397-430 pET28a-SUMO BamHI, XhoI S 
YALEHHH
HHH 37 °C / 2 hours 
27 scNup42 GBM F409D 397-430 pET28a-SUMO BamHI, XhoI S 
YALEHHH
HHH 37 °C / 2 hours 
28 scNup42 GBM F414D 397-430 pET28a-SUMO BamHI, XhoI S 
YALEHHH
HHH 37 °C / 2 hours 
29 scNup42 GBM F409D/F414D 397-430 
pET28a-
SUMO BamHI, XhoI S 
YALEHHH
HHH 37 °C / 2 hours 
30 scDbp5 1-482 pET28a-PreS NdeI, NotI GPHM - 18 °C / 18 hours 
31t hsDDX19 1-479 pET28a-PreS NdeI, NotI GPH - 18 °C / 18 hours 
32 ctDbp5 1-477 pETMCN-SUMO BamHI, NotI S - 18 °C / 18 hours 
33t hsDDX19 ∆N53 54-479 pET28a-PreS NdeI, NotI GPHM - 18 °C / 18 hours 
34 hsGle1 CTD H495A hsNup42 GBM 
382-698 
379-423 
pETDuet 
PreS 
NdeI, XhoI 
BamHI, NotI 
M 
GPSGS 
- 
- 18 °C / 18 hours 
35 hsGle1 CTD E491A hsNup42 GBM 
382-698 
379-423 
pETDuet 
PreS 
NdeI, XhoI 
BamHI, NotI 
M 
GPSGS 
- 
- 18 °C / 18 hours 
36 hsGle1 CTD E490A hsNup42 GBM 
382-698 
379-423 
pETDuet 
PreS 
NdeI, XhoI 
BamHI, NotI 
M 
GPSGS 
- 
- 18 °C / 18 hours 
37 hsGle1 CTD Q487A hsNup42 GBM 
382-698 
379-423 
pETDuet 
PreS 
NdeI, XhoI 
BamHI, NotI 
M 
GPSGS 
- 
- 18 °C / 18 hours 
38 hsGle1 CTD K486A hsNup42 GBM 
382-698 
379-423 
pETDuet 
PreS 
NdeI, XhoI 
BamHI, NotI 
M 
GPSGS 
- 
- 18 °C / 18 hours 
39 hsGle1 CTD K479A hsNup42 GBM 
382-698 
379-423 
pETDuet 
PreS 
NdeI, XhoI 
BamHI, NotI 
M 
GPSGS 
- 
- 18 °C / 18 hours 
40 hsGle1 CTD Q423A hsNup42 GBM 
382-698 
379-423 
pETDuet 
PreS 
NdeI, XhoI 
BamHI, NotI 
M 
GPSGS 
- 
- 18 °C / 18 hours 
41 hsGle1 CTD K416A/K419A hsNup42 GBM 
382-698 
379-423 
pETDuet 
PreS 
NdeI, XhoI 
BamHI, NotI 
M 
GPSGS 
- 
- 18 °C / 18 hours 
42 hsDDX19 ∆N67 68-479 pET28a-PreS NdeI, NotI GPHM - 18 °C / 18 hours 
43 hsDDX19 ∆N91 92-479 pET28a-PreS NdeI, NotI GPHM - 18 °C / 18 hours 
44 hsDDX19 S60D/K64D 1-479 pET28a-PreS NdeI, NotI GPH - 18 °C / 18 hours 
45 Nup214 NTD 1-405 pET28a-PreS NdeI, NotI GPH - 18 °C / 18 hours 
46 
hsGle1 CTD 
G666D/I669D/Q673D 
hsNup42 GBM 
382-698 
379-423 
pETDuet 
PreS 
NdeI, XhoI 
BamHI, NotI 
M 
GPSGS 
- 
- 18 °C / 18 hours 
47 hsGle1 CTD R569H hsNup42 GBM 
382-698 
379-423 
pETDuet 
PreS 
NdeI, XhoI 
BamHI, NotI 
M 
GPSGS 
- 
- 18 °C / 18 hours 
48 hsGle1 CTD V617M hsNup42 GBM 
382-698 
379-423 
pETDuet 
PreS 
NdeI, XhoI 
BamHI, NotI 
M 
GPSGS 
- 
- 18 °C / 18 hours 
49 hsGle1 CTD I684T hsNup42 GBM 
382-698 
379-423 
pETDuet 
PreS 
NdeI, XhoI 
BamHI, NotI 
M 
GPSGS 
- 
- 18 °C / 18 hours 
50 hsGle1 CTD R697C hsNup42 GBM 
382-698 
379-423 
pETDuet 
PreS 
NdeI, XhoI 
BamHI, NotI 
M 
GPSGS 
- 
- 18 °C / 18 hours 
51 hsDDX19 E243Q (DQAD) 1-479 pET28a-PreS NdeI, NotI GPH - 18 °C / 18 hours 
        
 
t Constructs that were used for crystallization 
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Supplementary Table 2.  
Yeast constructs 
Plasmid Protein Residues Vector Restriction 
Sites 5’, 3’ 
Selection 
pRS415-PNop1-mCherry N/A N/A pRS415 N/A LEU2 
pRS415-PNop1-NUP42-mCherry Nup42 1-430 pRS415 NdeI, SpeI LEU2 
pRS415-PNop1-nup42 (364-430)-mCherry Nup42 364-430 pRS415 NdeI, SpeI LEU2 
pRS415-PNop1-nup42 (397-430)-mCherry Nup42 397-430 pRS415 NdeI, SpeI LEU2 
 
 
 
Supplementary Table 3.  
RNA template constructs 
Plasmid nt Vector Ribozymes Modifications 
CTE FL 125 puc19 5’ HH, 3’ HDV - 
CTE V1 87 puc19 5’ HH, 3’ HDV - 
CTE V1 loops 87 puc19 5’ HH, 3’ HDV* 2 loops inserted in HDV 
CTE V3 77 puc19 5’ HH, 3’ HDV - 
CTE V3 loops 77 puc19 5’ HH*, 3’ HDV 2 loops inserted in HH- 
CTE ½  63 puc19 5’ HH, 3’ HDV - 
CTE ½ loops 63 puc19 5’ HH*, 3’ HDV 2 loops inserted in HH 
CTE ½-2  61 puc19 5’ HH, 3’ HDV - 
CTE ½-2  61 puc19 5’ HH*, 3’ HDV 2 loops inserted in HH- 
 
*loops inserted 
 
